KCM
EWTX icon

Kynam Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Kynam Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-253,979
Closed -$4.12M – 38
2025
Q3 		$4.12M Hold
253,979
– – 0.31% 33
2025
Q2 		$3.33M Buy
+253,979
New +$3.66M 0.36% 28

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Kynam Capital Management's EWTX Position: Q4 2025 in Review

Kynam Capital Management sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 253,979 shares — an estimated $4.12M sold.

Kynam Capital Management first reported a position in EWTX in Q2 2025 and held it in 2 quarters. The position peaked at $4.12M in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Kynam Capital Management reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kynam Capital Management sold 253,979 Edgewise Therapeutics shares in Q4 2025, an estimated $4.12M.
  • Kynam Capital Management first reported a position in Edgewise Therapeutics in Q2 2025 and held it in 2 quarters.
  • Kynam Capital Management's Edgewise Therapeutics position peaked at $4.12M in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Kynam Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.